Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
| 대상 질환 | Lupus Erythematosus, Lupus Nephritis |
|---|---|
| 임상 단계 | 1상 |
| 스폰서 | Biocon Limited |
| 상태 | 완료 |
| 참여자 수 | 52 명 |
| 중재(약물) | Itolizumab [Bmab 600] |
| 시작일 | 2019년 10월 1일 |
| 완료일 | 2023년 11월 16일 |
| 결과 공개일 | 2025년 4월 18일 |
요약
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis
Number of Treatment Emergent Adverse Events
| EQ001 Type A Cohort (0.4mg/kg) | 0 Participants |
|---|---|
| EQ001 for Type B Cohort | 17 Participants |
| EQ001 Type A Cohort (0.8mg/kg) | 2 Participants |
| EQ001 Type A Cohort (1.6mg/kg) | 4 Participants |
| EQ001 Type A Cohort (2.4mg/kg) | 3 Participants |
| EQ001 Type A Cohort (3.2mg/kg) | 8 Participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
- Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
- Reducing Disparities in Medication Adherence in SLE — Duke University
- Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health